In April 2025, JY Biomed Inc. and YC Biotech Inc. jointly announced the submission of their collaborative regenerative medicine clinical study for Parkinsonās Disease (PD) to the Joint Institutional Review Board of Taipei Medical University and its affiliated hospitals.
This study centers on the use of mesenchymal stem cells (MSCs) to evaluate their potential therapeutic application in patients with Parkinsonās Disease. As one of the few clinical initiatives in Taiwan targeting neurodegenerative conditions with regenerative approaches, the study represents a meaningful advancement in the field.
JY Biomed is the technology and patent holder for this project and serves as the study sponsor, leading the overall research strategy and direction. YC Biotech is responsible for the clinical trial execution, including study design, regulatory submission, and on-site trial management, ensuring compliance with GCP standards and regulatory requirements.
Together, the two companies aim to advance the clinical application of regenerative medicine in the treatment of Parkinsonās Disease and broaden the possibilities for therapeutic innovation in neurodegenerative disorders.
Ongoing updates on this project will be shared via the companiesā official websites and social media platforms.
